HD-OPM Archive
Topics › Cancer

Daraxonrasib nearly doubles survival in phase 3 pancreatic cancer trial

Louis Nervegna · Apr 16, 2026 · ♥ 5 reactions · 0 comments · original Facebook post
Cancer
AI summary & key facts

News that Revolution Medicines' drug daraxonrasib nearly doubled survival and cut death risk 60% versus chemotherapy in patients who had failed first-line therapy, per a company announcement. Not related to heart disease.

A new pancreatic cancer drug daraxonrasib DOUBLES overall survival time in a large phase 3 trial.

What is particularly impressive is that all these patients had already failed the standard-of-care first line therapy.

This drug is likely to get fast track approval by the FDA.

Full details:
cnb.cx/4tGgbDP

Quoted:

Revolution Medicines' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, almost doubling the typical length of survival and slashing the risk of death by 60% versus chemotherapy, the company said Monday.

#pancreaticcancerHD #daraxonrasibHD #cancerHD

← newer: Centenarians' higher LDL reflects survivorship bias, not benolder: CoQ10 supplements do not reliably prevent statin muscle symp →